Shares of Small Pharma Inc. (CVE:DMT – Get Free Report) traded down 6.3% on Friday . The stock traded as low as C$0.15 and last traded at C$0.15. 1,890,765 shares traded hands during trading, an increase of 538% from the average session volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Down 6.3 %
The company has a debt-to-equity ratio of 5.95, a current ratio of 2.63 and a quick ratio of 6.28. The company has a market capitalization of C$50.37 million, a price-to-earnings ratio of -2.14 and a beta of 0.86. The firm has a 50-day moving average price of C$0.15 and a two-hundred day moving average price of C$0.15.
About Small Pharma
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Featured Articles
- Five stocks we like better than Small Pharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Airline Stocks – Top Airline Stocks to Buy Now
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- How to Invest in Biotech Stocks
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
